Treats Human Immunodeficiency Virus (HIV-1) infection. ANDA 78128, held by Aurobindo Pharma. Zidovudine.
As of Nov 21, 2026, ANDA 78128 (Zidovudine), held by Aurobindo Pharma, was first approved by FDA on Mar 27, 2006, with 13 approved supplements and 0 published complete response letters.
Zidovudine capsules are a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. Prevention of maternal-fetal HIV-1 transmission. 1.1 Treatment of HIV-1 Zidovudine capsules, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 1.2 Prevention of Maternal-Fetal HIV-1 Transmission Zidovudine capsules are indicated for the prevention of maternal-fetal HIV-1 transmission.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2006 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zidovudine100MG · capsule;oral | Zidovudine | Rx |
| Apr 21, 2025 | Supplement 18Labeling · Standard review | Approved | None posted |
| Apr 21, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Apr 8, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 8, 2020 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 8, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 8, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 26, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 1, 2012 | Supplement 8Labeling | Approved | None posted |
| Aug 1, 2012 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 4, 2010 | Supplement 5Labeling | Approved | None posted |
| Jun 14, 2010 | Supplement 4Labeling | Approved | None posted |
| May 13, 2009 | Supplement 3Labeling | Approved | None posted |
| Jun 9, 2008 | Supplement 2Labeling | Approved | None posted |
| Mar 27, 2006 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters